A core tenet of precision oncology is the rational choice of drugs to interact with patient-specific biological targets of interest, but it is currently difficult for researchers to obtain consistent and well-supported target information for pharmaceutical drugs. We review current drug–target interaction resources and critically assess how supporting evidence is handled. We introduce the concept of a unified Cancer Targetome to aggregate drug–target interactions in an evidence-based framework. We discuss current unmet needs and the implications for evidence-based clinical omics. The focus of this review is precision oncology but the discussion is highly relevant to targeted therapies in any area.

精确肿瘤学的核心原则是合理选择药物，以与患者特定的感兴趣的生物靶标相互作用，但是目前，研究人员很难获得一致且得到充分支持的药物靶标信息。我们审查了当前的药物-靶标相互作用资源，并严格评估如何处理支持性证据。我们引入统一的癌症靶向组的概念，以在循证框架内汇总药物与靶标之间的相互作用。我们讨论了当前未满足的需求以及对基于证据的临床组学的影响。这篇综述的重点是精确肿瘤学，但是讨论与任何领域的靶向疗法高度相关。